WHAT IS CAR-T
CELL THERAPY?
A living treatment built from your own immune cells โ engineered to find and destroy cancer with precision no drug can match.
A Treatment Built From Your Own Biology
CAR-T therapy takes T-cells from a patient's own blood, genetically modifies them in a lab to carry a synthetic receptor (the CAR) that recognises a specific protein on cancer cells, expands them into hundreds of millions, and infuses them back. These cells are a living treatment โ they divide, persist, and keep working long after the infusion.
โCAR-T isn't a drug that circulates and gets cleared. It's a living treatment that can persist and keep fighting.โ
Approved CAR-T Products
Several CAR-T products are approved by regulatory agencies, each targeting a specific protein.
Yescarta (axi-cel)
CD19-targeting. Approved for large B-cell lymphomas and follicular lymphoma.
Kymriah (tisa-cel)
CD19-targeting. Approved for B-cell ALL (up to age 25) and DLBCL.
Breyanzi (liso-cel)
CD19-targeting. Approved for large B-cell lymphomas. Lowest severe CRS/ICANS rates.
Abecma (ide-cel)
BCMA-targeting. Approved for relapsed/refractory multiple myeloma.
Carvykti (cilta-cel)
BCMA-targeting. 97.9% ORR in myeloma. Strongest response data of any approved CAR-T.
Tecartus (brexu-cel)
CD19-targeting. Approved for mantle cell lymphoma and adult B-ALL.
Who Qualifies for CAR-T?
CAR-T is approved for patients with relapsed or treatment-resistant blood cancers.
B-Cell Lymphomas
DLBCL, follicular, mantle cell, primary mediastinal โ after 2+ prior treatment lines.
B-Cell ALL
Children and young adults with relapsed/refractory B-ALL. Strongest remission data: 70-90% CR.
Multiple Myeloma
After multiple prior lines including PI, IMiD, and anti-CD38 antibody.
Benefits vs Limitations
What Sets CAR-T Apart
- Single infusion, not a recurring cycleOne treatment with potential for lasting response.
- Built from the patient's own cellsPersonalised to each patient's cancer.
- Complete remissions in previously exhausted patientsOutcomes not achievable with prior treatments.
What Patients Must Know
- Response is not guaranteedNot every eligible patient achieves remission.
- CRS and neurotoxicity require hospital monitoringSerious side effects managed at specialist centres.
- 3-5 week manufacturing windowDisease must remain stable during this period.
Frequently Asked Questions
About CAR-T Cell Therapy
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Want to Know If CAR-T Is an Option for You?
A case evaluation with a cellular therapy specialist is the right first step. Upload your reports for a free assessment.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.